X-Bi­otix sus­pends R&D ef­forts amid dearth of fi­nanc­ing for an­tibi­otics re­search; Ver­tex picks a pain drug for mid-stage stud­ies

Lament­ing the dearth of fi­nanc­ing avail­able for an­tibi­otics re­search de­spite a grow­ing de­mand for new prod­ucts to fight drug re­sis­tance, lit­tle Waltham, MA-based X-Bi­otix has sus­pend­ed its own R&D ef­forts in the field while con­tin­u­ing to try to hunt up fresh back­ing.

Fund­ed with a small A round in 2018, X-Bi­otix says it will now look to back up its IP and pub­lish man­u­scripts as re­search work laps­es.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER